Hans Christoph Tanner

Dr. Hans Christoph Tanner, Board Member


Dr. Chris Tanner is a member of the executive management of Cosmo Pharmaceuticals NV (SIX:COPN), a specialty pharmaceutical company in Gastrointestinal Disorders and Endoscopic Procedures and Cassiopea SpA (SIX:SKIN), a clinical-stage specialty pharmaceutical company in dermatology.

He is a member of the board of Cosmo Pharmaceuticals NV (SIX:COPN), DKSH AG (SIX:DKSH), Private Equity Holding AG (SIX:PEHN), PAION AG (ETR: PA8), CureVac AG, a mRNA company, Joimax GmbH, a med tech company in minimally invasive back surgery and he is a member of the evaluation board of Wyss Zurich.

Chris Tanner was at UBS from 1977 to 1998. He was a co-founder of the newspaper group 20 Minutes in 1999, a co-investor in Plus Endoprothetik AG in 2001, and after raising the financing for Cosmo Pharmaceuticals in 2005, joined it in 2006 and brought it public in 2007. In 2015 he led the spin-off of Cassiopea SpA from Cosmo Pharmaceuticals.

Chris Tanner has a diploma (Lic Oec) in macroeconomics from the University of St.Gallen and a PhD on steering migration in developing countries from the University of St. Gallen.